Medicure Inc. (V:MPH)
Business Focus: Bio Therapeutic Drugs
Apr 08, 2024 05:00 pm ET
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023
WINNIPEG, MB / ACCESSWIRE / April 8, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTCPINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter and year ended December 31, 2023.
Apr 04, 2024 06:00 pm ET
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
WINNIPEG, MB / ACCESSWIRE / April 4, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Year End Financial Results on a Conference Call on April 9, 2024 at 8:30 am Eastern Time. The 2023 Year End Financials will be filed after closing April 8, 2024.
Dec 05, 2023 05:00 pm ET
Medicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy(R) as an Affordable Medication for Americans with Type 2 Diabetes
WINNIPEG, MB / ACCESSWIRE / December 5, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, through its pharmacy subsidiary Marley Drug®, a trusted national pharmacy known for its commitment to affordable healthcare solutions, is pleased to announce a partnership with TheracosBio to distribute a newly approved diabetes drug, BRENZAVVY® (bexag
Nov 23, 2023 05:00 pm ET
Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease
WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5′-phosphate oxi
Nov 21, 2023 05:00 pm ET
Medicure Reports Financial Results for Quarter Ended September 30, 2023
WINNIPEG, MB / ACCESSWIRE / November 21, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2023.
Aug 29, 2023 06:00 pm ET
Medicure Reiterates its Commitment to Providing Exceptional Access to its Branded Pitavastatin (Zypitamag) to People Living With HIV
WINNIPEG, MB / ACCESSWIRE / August 29, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reaffirms its commitment to providing affordable and straightforward access to its branded pitavastatin, ZYPITAMAG®, to people living with HIV through two important channels: its pharmacy subsidiary Marley Drug® and through the AIDS Drug Assistan
Jul 28, 2023 08:00 pm ET
Medicure Reports Financial Results For Quarter Ended June 30, 2023
WINNIPEG, MB / ACCESSWIRE / July 28, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2023.
Jul 24, 2023 07:00 pm ET
Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023
WINNIPEG, MB / ACCESSWIRE / July 24, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Q2 Financial Results on a Conference Call on July 31, 2023 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing July 28th, 2023.
May 26, 2023 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended March 31, 2023
WINNIPEG, MB / ACCESSWIRE / May 26, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2023.
Apr 06, 2023 05:00 pm ET
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2022
WINNIPEG, MB / ACCESSWIRE / April 6, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter and year ended December 31, 2022.
Apr 05, 2023 02:00 pm ET
Medicure To Present Financial Results on April 10, 2023 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2022
WINNIPEG, MB / ACCESSWIRE / April 5, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2022 Year End Financial Results on a Conference Call on April 10, 2023 at 8:30 am Eastern Time. The 2022 Year End Financials will be filed after closing on April 6, 2023 ahead of the Good Friday holiday on April 7, 2023 (markets closed)
Feb 01, 2023 06:00 am ET
MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS
WINNIPEG, MB, Feb. 1, 2023 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004.
Feb 01, 2023 06:00 am ET
MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS
WINNIPEG, MB, Feb. 1, 2023 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004.
Nov 24, 2022 04:00 pm ET
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2022
WINNIPEG, MB, Nov. 24, 2022 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2022.
Nov 24, 2022 04:00 pm ET
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2022
WINNIPEG, MB, Nov. 24, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2022.
Nov 17, 2022 04:00 pm ET
MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022
WINNIPEG, MB, Nov. 17, 2022 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q3 Financial Results on a Conference Call on November 25, 2022 at 8:30 am Eastern Time. The Q3 Financials will be filed after closing the day before.
Nov 17, 2022 04:00 pm ET
MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022
WINNIPEG, MB, Nov. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q3 Financial Results on a Conference Call on November 25, 2022 at 8:30 am Eastern Time. The Q3 Financials will be filed after closing the day before.
Sep 26, 2022 09:00 am ET
EARLY WARNING NEWS RELEASE - DR. ALBERT D. FRIESEN'S HOLDINGS IN MEDICURE INC.
WINNIPEG, MB, Sept. 26, 2022 /CNW/ - This release is being issued in connection with the filing of an early warning report (the "Early Warning Report") pursuant to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding the change in the ownership and control of common shares (the "Common Shares") of Medicure Inc. (the "Issuer") by Dr. Albert D. Friesen ("Dr. Friesen"). The Issuer's head office address and Dr. Friesen's business address is 2-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6.
Sep 26, 2022 09:00 am ET
EARLY WARNING NEWS RELEASE - DR. ALBERT D. FRIESEN'S HOLDINGS IN MEDICURE INC.
WINNIPEG, MB, Sept. 26, 2022 /PRNewswire/ - This release is being issued in connection with the filing of an early warning report (the "Early Warning Report") pursuant to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding the change in the ownership and control of common shares (the "Common Shares") of Medicure Inc. (the "Issuer") by Dr. Albert D. Friesen ("Dr. Friesen"). The Issuer's head office address and Dr. Friesen's business address is 2-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6.
Aug 24, 2022 05:00 pm ET
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2022
WINNIPEG, MB, Aug. 24, 2022 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2022.
Aug 24, 2022 05:00 pm ET
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2022
WINNIPEG, MB, Aug. 24, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2022.
Aug 17, 2022 05:00 pm ET
MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022
WINNIPEG, MB, Aug. 17, 2022 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q2 Financial Results on a Conference Call on August 25, 2022 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing the day before.
Aug 17, 2022 05:00 pm ET
MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022
WINNIPEG, MB, Aug. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q2 Financial Results on a Conference Call on August 25, 2022 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing the day before.
Jun 20, 2022 05:00 pm ET
MEDICURE ANNOUNCES RESULTS OF 2022 AGM
WINNIPEG, MB, June 20, 2022 /CNW/ - (June 20, 2022) Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce that the following individuals were elected as directors at its Annual General Meeting of shareholders held on June 16, 2022: Dr. Albert Friesen, Gerald McDole, Brent Fawkes, Dr. Arnold Naimark, Peter Quick and James Kinley. In addition, the shareholders re-appointed Ernst & Young LLP,
Jun 20, 2022 05:00 pm ET
MEDICURE ANNOUNCES RESULTS OF 2022 AGM
WINNIPEG, MB, June 20, 2022 /PRNewswire/ - (June 20, 2022) Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce that the following individuals were elected as directors at its Annual General Meeting of shareholders held on June 16, 2022: Dr. Albert Friesen, Gerald McDole, Brent Fawkes, Dr. Arnold Naimark, Peter Quick and James Kinley. In addition, the shareholders re-appointed Ernst & Youn
May 30, 2022 07:00 pm ET
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2022 AND APPOINTMENT OF HAARIS UDDIN AS CHIEF FINANCIAL OFFICER
WINNIPEG, MB, May 30, 2022 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2022, and is pleased to also announce the appointment of Mr. Haaris Uddin (CPA, B.Comm.) as Chief Financial Officer, effective June 1, 2022.
May 30, 2022 07:00 pm ET
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2022 AND APPOINTMENT OF HAARIS UDDIN AS CHIEF FINANCIAL OFFICER
WINNIPEG, MB, May 30, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2022, and is pleased to also announce the appointment of Mr. Haaris Uddin (CPA, B.Comm.) as Chief Financial Officer, effective June 1, 2022.
Apr 27, 2022 08:00 pm ET
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2021
WINNIPEG, MB, April 27, 2022 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter and year ended December 31, 2021.
Apr 27, 2022 08:00 pm ET
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2021
WINNIPEG, MB, April 27, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter and year ended December 31, 2021.
Apr 26, 2022 01:00 pm ET
MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST
WINNIPEG, MB, April 26, 2022 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announces Medicure's 2021 Year End Results Conference Call.
Apr 26, 2022 01:00 pm ET
MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST
WINNIPEG, MB, April 26, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announces Medicure's 2021 Year End Results Conference Call.
Mar 23, 2022 05:00 pm ET
MEDICURE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER AND SUCCESSION PLAN
WINNIPEG, MB, March 23, 2022 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported that Chief Financial Officer David Gurvey (CPA, CMA, B.Sc.) is resigning, effective March 25, 2022.
Mar 23, 2022 05:00 pm ET
MEDICURE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER AND SUCCESSION PLAN
WINNIPEG, MB, March 23, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported that Chief Financial Officer David Gurvey (CPA, CMA, B.Sc.) is resigning, effective March 25, 2022.
Feb 22, 2022 08:00 am ET
Medicure's Subsidiary - Marley Drug to Partner with RxSpark, the Next Generation in Pharmacy Discount Programs, to be its Sole Mail-Order Pharmacy
WINNIPEG, MB, Feb. 22, 2022 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce the integration of its subsidiary, Marley Drug® pharmacy, as the sole mail-order pharmacy for RxSpark™, the next generation in pharmacy discount programs.
Feb 22, 2022 08:00 am ET
Medicure's Subsidiary - Marley Drug to Partner with RxSpark, the Next Generation in Pharmacy Discount Programs, to be its Sole Mail-Order Pharmacy
WINNIPEG, MB, Feb. 22, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce the integration of its subsidiary, Marley Drug® pharmacy, as the sole mail-order pharmacy for RxSpark™, the next generation in pharmacy discount programs.
Feb 09, 2022 08:53 am ET
Medicure Launches E-Commerce Pharmacy Platform - www.marleydrug.com Through its Subsidiary Marley Drug Pharmacy
WINNIPEG, MB, Feb. 9, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce that it has launched its national direct-to-consumer E-Commerce pharmacy platform – www.marleydrug.com through its subsidiary, Marley Drug® pharmacy.
Nov 30, 2021 07:00 am ET
Algernon Pharmaceuticals Announces New Chief Financial Officer
Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has appointed Mr. James Kinley as the Company’s Chief...
Nov 22, 2021 04:00 pm ET
Medicure Reports Financial Results for Quarter Ended September 30, 2021
WINNIPEG, MB, Nov. 22, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2021.
Nov 22, 2021 04:00 pm ET
Medicure Reports Financial Results for Quarter Ended September 30, 2021
WINNIPEG, MB, Nov. 22, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2021.
Nov 22, 2021 08:00 am ET
Medicure Plans To Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly To Millions of Americans
WINNIPEG, MB, Nov. 22, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce that it is planning to launch a national direct-to-consumer E-Commerce pharmacy platform through its subsidiary, Marley Drug™ pharmacy, before the end of 2021.
Nov 22, 2021 08:00 am ET
Medicure Plans To Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly To Millions of Americans
WINNIPEG, MB, Nov. 22, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce that it is planning to launch a national direct-to-consumer E-Commerce pharmacy platform through its subsidiary, Marley Drug™ pharmacy, before the end of 2021.
Nov 04, 2021 05:00 pm ET
Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint
WINNIPEG, MB, Nov. 4, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the results from the SAVI-PCI clinical trial demonstrating that the use of short infusion AGGRASTAT® (tirofiban hydrochloride) injection was non-inferior to label-dosing INTEGRILIN® (eptifibatide) or long-infusion AGGRASTAT® in a primary endpoint of combined efficacy and major bleeding.
Nov 04, 2021 05:00 pm ET
Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint
WINNIPEG, MB, Nov. 4, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the results from the SAVI-PCI clinical trial demonstrating that the use of short infusion AGGRASTAT® (tirofiban hydrochloride) injection was non-inferior to label-dosing INTEGRILIN® (eptifibatide) or long-infusion AGGRASTAT® in a primary endpoint of combined efficacy and major bleeding.
Aug 27, 2021 05:00 pm ET
Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021
WINNIPEG, MB, Aug. 27, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2021.
Aug 27, 2021 05:00 pm ET
Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021
WINNIPEG, MB, Aug. 27, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2021.
Jul 30, 2021 08:00 am ET
Medicure Announces Grant of Stock Options
WINNIPEG, MB, July 30, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that it has granted stock options (the "Options") to certain officers of the Company to purchase a total of 90,000 common shares at a price of $1.10 per common share. The Options, which vest immediately, are exercisable for a period of five years and have been granted in accordance with the terms of the Company's c
Jul 30, 2021 08:00 am ET
Medicure Announces Grant of Stock Options
WINNIPEG, MB, July 30, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that it has granted stock options (the "Options") to certain officers of the Company to purchase a total of 90,000 common shares at a price of $1.10 per common share. The Options, which vest immediately, are exercisable for a period of five years and have been granted in accordance with the terms of the Comp
Jun 24, 2021 05:01 pm ET
Medicure Announces Appointment of David Gurvey as Chief Financial Officer
WINNIPEG, MB, June 24, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce the appointment of Mr. David Gurvey (CPA, CMA, B.Sc.) as Chief Financial Officer, effective June 28, 2021.
Jun 24, 2021 05:01 pm ET
Medicure Announces Appointment of David Gurvey as Chief Financial Officer
WINNIPEG, MB, June 24, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce the appointment of Mr. David Gurvey (CPA, CMA, B.Sc.) as Chief Financial Officer, effective June 28, 2021.
May 10, 2021 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended March 31, 2021
WINNIPEG, May 10, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2021.
May 05, 2021 03:03 pm ET
Medicure 2020 Annual and Q1 2021 Results and Conference Call Date
WINNIPEG, MB, May 5, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will release financial results for the quarter ended March 31, 2021 on Monday, May 10, 2021. The first quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the 2020 annual and Q1 2021 results on Tuesday, May 11, 2021 at 7:30 AM
Apr 28, 2021 05:01 pm ET
Medicure Announces Resignation of Chief Financial Officer and Succession Plan
WINNIPEG, MB, April 28, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported that after nearly 10 years with Medicure, Chief Financial Officer James Kinley (CPA, CA) is resigning, effective May 15, 2021, to pursue another business opportunity. The Company thanks James for his significant contributions and leadership.
Apr 20, 2021 06:00 pm ET
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2020
Conference call to be held in connection with the Company's Q1 2021 results to be released in May 2021
Mar 29, 2021 07:26 pm ET
Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 30, 2021
WINNIPEG, MB, March 29, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, March 30, 2021 at 1:00 PM EST (12:00 PM CST, 11:00 AM MST). Medicure welcomes stakeholders, investors, and other individual followers to register and attend this live event.
Mar 08, 2021 04:30 pm ET
Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 9, 2021
WINNIPEG, MB, March 8, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, March 9, 2021 at 12:00 PM EST (11:00 AM CST, 10:00 AM MST). Medicure welcomes stakeholders, investors, and other individual followers to register and attend this live event.
Feb 22, 2021 05:17 pm ET
Feb 22, 2021 05:17 pm ET
Feb 04, 2021 04:30 pm ET
Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021
WINNIPEG, MB, Feb. 4, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH) (OTC:MCUJF), announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 8, 2021 at 2:00 PM EST (1:00 PM CST, 12:00 PM MST). Medicure welcomes stakeholders, investors, and other individual followers to register and attend this live event.
Feb 04, 2021 04:30 pm ET
Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021
WINNIPEG, MB, Feb. 4, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH) (OTC:MCUJF), announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 8, 2021 at 2:00 PM EST (1:00 PM CST, 12:00 PM MST). Medicure welcomes stakeholders, investors, and other individual followers to register and attend this live event.
Jan 27, 2021 04:30 pm ET
Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets
WINNIPEG, MB, Jan. 27, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the early completion of iSPASM, a randomized, double-blind, single-center, Phase 1/2a trial aimed at assessing the safety of long-term (7-day) use of AGGRASTAT® (tirofiban hydrochloride) injection (an intravenous GP IIb/IIIa inhibitor) vs. placebo in patients with aneurysmal subarachnoid hemorrhage (aSAH) (NCT03691727). The primary endpoint in the 30 patient study was hemorrhagic changes evident on head CT and/or MRI assesse
Jan 27, 2021 04:30 pm ET
Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets
WINNIPEG, MB, Jan. 27, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the early completion of iSPASM, a randomized, double-blind, single-center, Phase 1/2a trial aimed at assessing the safety of long-term (7-day) use of AGGRASTAT® (tirofiban hydrochloride) injection (an intravenous GP IIb/IIIa inhibitor) vs. placebo in patients with aneurysmal subarachnoid hemorrhage (aSAH) (NCT03691727). The primary endpoint in the 30 patient study was hemorrhagic changes evident on head CT and/or MRI
Jan 07, 2021 04:30 pm ET
Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency
WINNIPEG, MB, Jan. 7, 2021 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announced that through its Barbados subsidiary, Medicure International Inc., it intends to file an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") pertaining to its legacy product Pyridoxal 5′-phosphate ("P5P", also referred to as "MC-1") for the treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase ("PNPO") deficiency. The majority of patients with PNPO deficiency have mutat
Jan 07, 2021 04:30 pm ET
Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency
WINNIPEG, MB, Jan. 7, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announced that through its Barbados subsidiary, Medicure International Inc., it intends to file an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") pertaining to its legacy product Pyridoxal 5′-phosphate ("P5P", also referred to as "MC-1") for the treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase ("PNPO") deficiency. The majority of patients with PNPO deficiency hav
Dec 17, 2020 07:00 am ET
Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug
WINNIPEG, MB, Dec. 17, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announced that, through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., it entered into a definitive agreement on December 15, 2020, to acquire 100% of Marley Drug, Inc ("Marley"), a leading specialty pharmacy serving more than 30,000 customers across the United States, from an arms-length third-party, for an upfront payment on closing of USD $6.3 million, subject to certain holdbacks, as well as additional payments based on future p
Dec 17, 2020 07:00 am ET
Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug
WINNIPEG, MB, Dec. 17, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announced that, through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., it entered into a definitive agreement on December 15, 2020, to acquire 100% of Marley Drug, Inc ("Marley"), a leading specialty pharmacy serving more than 30,000 customers across the United States, from an arms-length third-party, for an upfront payment on closing of USD $6.3 million, subject to certain holdbacks, as well as additional payments based on f
Dec 02, 2020 08:00 am ET
Medicure Retains Investor Relations Firm Renmark Financial Communications Inc.
NEW INVESTOR SLIDE PRESENTATION AVAILABLE AT WWW.MEDICURE.COM/INVESTORS
Dec 02, 2020 08:00 am ET
Medicure Retains Investor Relations Firm Renmark Financial Communications Inc.
NEW INVESTOR SLIDE PRESENTATION AVAILABLE AT WWW.MEDICURE.COM/INVESTORS
Nov 18, 2020 05:00 pm ET
Medicure Announces Settlement of Patent Infringement Action
WINNIPEG, MB, Nov. 18, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Nexus Pharmaceuticals, Inc. ("Nexus") in the U.S. District Court for the Northern District of Illinois, which alleged infringement of Medicure's U.S. Patent No. 6,770,660 ("the '660 patent"). As part of the settlement, Nexus has acknowledged that the '660 patent is valid, enforceable and infringed. The settlement results in
Nov 18, 2020 05:00 pm ET
Medicure Announces Settlement of Patent Infringement Action
WINNIPEG, MB, Nov. 18, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Nexus Pharmaceuticals, Inc. ("Nexus") in the U.S. District Court for the Northern District of Illinois, which alleged infringement of Medicure's U.S. Patent No. 6,770,660 ("the '660 patent"). As part of the settlement, Nexus has acknowledged that the '660 patent is valid, enforceable and infringed. The settlement resu
Nov 11, 2020 04:00 pm ET
Medicure Reports Financial Results for Quarter Ended September 30, 2020
WINNIPEG, MB, Nov. 11, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH) (OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2020.
Nov 11, 2020 04:00 pm ET
Medicure Reports Financial Results for Quarter Ended September 30, 2020
WINNIPEG, MB, Nov. 11, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH) (OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2020.
Nov 05, 2020 05:41 pm ET
Medicure Q3 2020 Results and Conference Call Dates
WINNIPEG, MB, Nov. 5, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended September 30, 2020 on Wednesday, November 11, 2020. The third quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, November 12, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).
Nov 05, 2020 05:41 pm ET
Medicure Q3 2020 Results and Conference Call Dates
WINNIPEG, MB, Nov. 5, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended September 30, 2020 on Wednesday, November 11, 2020. The third quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, November 12, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).
Oct 05, 2020 08:30 am ET
Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar
WINNIPEG, AB, Oct. 5, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, announces that through its wholly-owned subsidiary, Medicure International Inc., it has entered into a License, Manufacture and Supply Agreement (the "Agreement") with Reliance Life Sciences Private Limited ("RLS") for a cardiovascular biosimilar (the "Product"). Medicure is responsible for the regulatory approval process for the Product. A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an approved r
Aug 24, 2020 02:00 pm ET
Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports
WINNIPEG, MB, Aug. 24, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is reporting that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT® (tirofiban hydrochloride) show promise for preventing and treating thrombotic complications due to COVID-19. AGGRASTAT® is not currently indicated for use in patients with COVID-19.
Aug 20, 2020 06:10 pm ET
Medicure Announces Termination of ReDSTM Pro Marketing and Distribution Agreement
STRENGTHENS FOCUS ON MARKETING OF AGGRASTAT® AND ZYPITAMAGTM
Aug 11, 2020 05:00 pm ET
Medicure Reports Financial Results for Quarter Ended June 30, 2020
WINNIPEG, MB, Aug. 11, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2020.
Aug 05, 2020 12:02 pm ET
Medicure Q2 2020 Results and Conference Call Dates
WINNIPEG, MB, Aug. 5, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended June 30, 2020 on Tuesday, August 11, 2020. The second quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Wednesday, August 12, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).
Aug 05, 2020 12:02 pm ET
Medicure Q2 2020 Results and Conference Call Dates
WINNIPEG, MB, Aug. 5, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended June 30, 2020 on Tuesday, August 11, 2020. The second quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Wednesday, August 12, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).
Jun 29, 2020 05:30 pm ET
Medicure Announces Normal Course Issuer Bid
WINNIPEG, MB, June 29, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted the Company's notice of intention to make a normal course issuer bid ("NCIB").
Jun 29, 2020 05:30 pm ET
Medicure Announces Normal Course Issuer Bid
WINNIPEG, MB, June 29, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted the Company's notice of intention to make a normal course issuer bid ("NCIB").
Jun 29, 2020 09:06 am ET
Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation
WINNIPEG, MB, June 29, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT®, have been published in Circulation, a peer-reviewed journal of the American Heart Association.
Jun 29, 2020 09:06 am ET
Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation
WINNIPEG, MB, June 29, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT®, have been published in Circulation, a peer-reviewed journal of the American Heart Association.
Jun 25, 2020 08:30 am ET
Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG™ (Pitavastatin) Tablets
WINNIPEG, MB, June 25, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH), (OTC:MCUJF), a pharmaceutical company, is pleased to announce the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAGTM in the United States.
Jun 25, 2020 08:30 am ET
Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG™ (Pitavastatin) Tablets
WINNIPEG, MB, June 25, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH), (OTC:MCUJF), a pharmaceutical company, is pleased to announce the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAGTM in the United States.
Jun 18, 2020 11:45 am ET
C-Suite At The Open: Albert Friessen, Chair & CEO from Medicure Inc. tells his Company story. Filmed May 2020.
TORONTO, June 18, 2020 /CNW/ -
Jun 15, 2020 01:48 pm ET
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020
WINNIPEG, MB, June 15, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is pleased to announce that on Saturday, June 27, 2020, Dr. Marco Valgimigli, MD, PhD, Professor of Cardiology, Director of Clinical Research at Bern University Hospital, will present the results of the FABOLUS-FASTER Phase 4 clinical trial. The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) i
Jun 15, 2020 01:48 pm ET
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020
WINNIPEG, MB, June 15, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is pleased to announce that on Saturday, June 27, 2020, Dr. Marco Valgimigli, MD, PhD, Professor of Cardiology, Director of Clinical Research at Bern University Hospital, will present the results of the FABOLUS-FASTER Phase 4 clinical trial. The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhib
May 12, 2020 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended March 31, 2020
WINNIPEG, May 12, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2020.
May 12, 2020 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended March 31, 2020
WINNIPEG, May 12, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2020.
May 06, 2020 05:00 pm ET
Medicure Q1 2020 results and conference call dates
WINNIPEG, May 6, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended March 31, 2020 on Tuesday, May 12, 2020. The first quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Wednesday, May 13, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).
May 06, 2020 05:00 pm ET
Medicure Q1 2020 results and conference call dates
WINNIPEG, May 6, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended March 31, 2020 on Tuesday, May 12, 2020. The first quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Wednesday, May 13, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).
Apr 15, 2020 06:00 pm ET
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2019
WINNIPEG, April 15, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter and year ended December 31, 2019.
Apr 15, 2020 06:00 pm ET
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2019
WINNIPEG, April 15, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter and year ended December 31, 2019.
Apr 13, 2020 12:02 pm ET
Medicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020
WINNIPEG, April 13, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the year ended December 31, 2019 on Wednesday, April 15, 2020. The financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, April 16, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).
Apr 13, 2020 12:02 pm ET
Medicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020
WINNIPEG, April 13, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the year ended December 31, 2019 on Wednesday, April 15, 2020. The financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, April 16, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).
Dec 31, 2019 07:30 am ET
Early Warning News Release - Dr. Albert D. Friesen Holdings in Medicure Inc.
WINNIPEG, Dec. 31, 2019 /CNW/ - This press release is being issued in connection with the filing of an early warning report (the "Early Warning Report") pursuant to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding the change in the ownership and control of common shares (the "Common Shares") of Medicure Inc. (the "Issuer") by Dr. Albert D. Friesen ("Dr. Friesen"). The Issuer's head office address and Dr. Friesen's business address is 2-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6.
Dec 20, 2019 08:00 am ET
Medicure Announces Preliminary Results of Substantial Issuer Bid
WINNIPEG, Dec. 20, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, announced today the preliminary results of its substantial issuer bid (the "Offer") to repurchase for cancellation up to 4.0 million of its common shares (the "Common Shares") at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash. The Offer expired at 5:00 p.m. (Eastern Standard Time) on December 19, 2019.
Dec 17, 2019 04:30 pm ET
Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study
WINNIPEG, Dec. 17, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the Shortened AGGRASTAT® (tirofiban hydrochloride) injection versus Integrilin® (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial.
Dec 12, 2019 05:00 pm ET
Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coro
WINNIPEG, Dec. 12, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH), (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the FABOLUS-FASTER Phase 4 trial, a randomized, open-label, multi-center trial assessing different regimens of intravenous platelet inhibitors, notably tirofiban (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI. The study enrolled 120 patients. Medicure expects to release top-line data in Q1 of 2020.
Dec 05, 2019 05:00 pm ET
Medicure Announces Settlement of Holdback Dispute from Apicore Sale
WINNIPEG, Dec. 5, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that it has reached a settlement agreement with the purchaser of Medicure's interests in Apicore with respect to the amounts heldback under the Apicore sale agreement. A settlement agreement was reached under which Medicure will receive a net payment of US$5.1 million in relation to the holdback.
Dec 05, 2019 04:29 pm ET
Medicure Files Patent Infringement Action
WINNIPEG, Dec. 5, 2019 /CNW/ - Medicure Inc. ("Medicure") (TSXV: MPH, OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has filed a patent infringement action against Nexus Pharmaceuticals, Inc. ("Nexus") in the U.S. District Court for the Northern District of Illinois, alleging infringement of U.S. Patent No. 6,770,660 ("the '660 patent").
Nov 26, 2019 04:30 pm ET
Medicure Reports Financial Results for Quarter Ended September 30, 2019
WINNIPEG, Nov. 26, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2019.
Nov 19, 2019 04:00 pm ET
Medicure Q3 2019 Results and Conference Call Dates
WINNIPEG, Nov. 19, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended September 30, 2019 on Tuesday, November 26, 2019. The third quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Wednesday, November 27, 2019 at 7:30 AM Central Time (8:30 AM Eastern Time).
Nov 13, 2019 04:00 pm ET
Medicure Announces Commencement of Substantial Issuer Bid
WINNIPEG, Nov. 13, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJF), a cardiovascular pharmaceutical company, today announced the commencement of its previously announced substantial issuer bid (the "Offer"), pursuant to which the Company offers to purchase up to 4.0 million of its common shares (the "Common Shares") for cancellation at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash. The Offer will expire at 5:00 p.m. (Eastern Standard time) on December 19, 2019, unless extended or withdrawn by Medicure
Nov 13, 2019 04:00 pm ET
Medicure Announces Commencement of Substantial Issuer Bid
WINNIPEG, Nov. 13, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJF), a cardiovascular pharmaceutical company, today announced the commencement of its previously announced substantial issuer bid (the "Offer"), pursuant to which the Company offers to purchase up to 4.0 million of its common shares (the "Common Shares") for cancellation at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash. The Offer will expire at 5:00 p.m. (Eastern Standard time) on December 19, 2019, unless extended or withdrawn by M
Nov 04, 2019 05:00 am ET
Medicure Announces Intention to Commence Substantial Issuer Bid
WINNIPEG, Nov. 4, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced its intention to commence a substantial issuer bid (the "Offer") pursuant to which the Company will offer to purchase up to 4.0 million of its common shares (the "Common Shares") for cancellation at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash. The Offer will be funded from the Company's existing cash on hand.
Nov 04, 2019 05:00 am ET
Medicure Announces Intention to Commence Substantial Issuer Bid
WINNIPEG, Nov. 4, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced its intention to commence a substantial issuer bid (the "Offer") pursuant to which the Company will offer to purchase up to 4.0 million of its common shares (the "Common Shares") for cancellation at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash. The Offer will be funded from the Company's existing cash on hand.
Oct 15, 2019 08:30 am ET
Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate
WINNIPEG, Oct. 15, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the primary results of the late-breaking SMILETM-Heart Failure (SMILE-HF) Clinical Trial which was presented at the recent Heart Failure Society of America ("HFSA") conference in Philadelphia, PA by Dr. William T. Abraham, the SMILE-HF national principal investigator.
Oct 15, 2019 08:30 am ET
Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate
WINNIPEG, Oct. 15, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the primary results of the late-breaking SMILETM-Heart Failure (SMILE-HF) Clinical Trial which was presented at the recent Heart Failure Society of America ("HFSA") conference in Philadelphia, PA by Dr. William T. Abraham, the SMILE-HF national principal investigator.
Oct 03, 2019 06:00 pm ET
Medicure Announces Preferred Pricing Agreement for Zypitamag™ with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force
WINNIPEG, Oct. 3, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJD.PK), a cardiovascular pharmaceutical company, is pleased to announce that it has reached a preferred pricing agreement with the AIDS Drug Assistance Program (ADAP) Crisis Task Force for ZYPITAMAGTM (pitavastatin) tablets. The agreement will open access to ZYPITAMAGTM tablets to low income, underinsured and uninsured Americans who qualify for ADAP coverage in states where ZYPITAMAG has been adopted onto the ADAP formulary.
Oct 03, 2019 06:00 pm ET
Medicure Announces Preferred Pricing Agreement for Zypitamag™ with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force
WINNIPEG, Oct. 3, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJD.PK), a cardiovascular pharmaceutical company, is pleased to announce that it has reached a preferred pricing agreement with the AIDS Drug Assistance Program (ADAP) Crisis Task Force for ZYPITAMAGTM (pitavastatin) tablets. The agreement will open access to ZYPITAMAGTM tablets to low income, underinsured and uninsured Americans who qualify for ADAP coverage in states where ZYPITAMAG has been adopted onto the ADAP formulary.
Sep 30, 2019 06:30 am ET
Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag™
WINNIPEG, Sept. 30, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that through its subsidiary, Medicure International Inc., it has acquired the ownership of ZYPITAMAGTM (pitavastatin) tablets, from Cadila Healthcare Ltd., India ("Zydus") for US and Canadian markets. Under terms of the agreement, Zydus will receive an upfront payment of U.S. $5,000,000 and U.S. $2,000,000 in deferred payments to be made over the next four years, as well as contingent payments on achievement of milestones and roya
Sep 30, 2019 06:30 am ET
Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag™
WINNIPEG, Sept. 30, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that through its subsidiary, Medicure International Inc., it has acquired the ownership of ZYPITAMAGTM (pitavastatin) tablets, from Cadila Healthcare Ltd., India ("Zydus") for US and Canadian markets. Under terms of the agreement, Zydus will receive an upfront payment of U.S. $5,000,000 and U.S. $2,000,000 in deferred payments to be made over the next four years, as well as contingent payments on achievement of milestones a
Sep 17, 2019 09:59 am ET
Medicure Announces Launch of New and Improved ReDS™ PRO
WINNIPEG, Sept. 17, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the launch of the ReDSTM PRO ("ReDSTM PRO") system, the next generation of lung fluid management technology for heart failure. The debut of the new system took place at the recent Heart Failure Society of America ("HFSA") conference in Philadelphia, PA. ReDSTM PRO is optimized for the point-of-care market, designed for use in hospitals and sub-acute facilities. ReDSTM PRO utilizes non-invasive low energy radio frequency technology
Sep 17, 2019 09:59 am ET
Medicure Announces Launch of New and Improved ReDS™ PRO
WINNIPEG, Sept. 17, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the launch of the ReDSTM PRO ("ReDSTM PRO") system, the next generation of lung fluid management technology for heart failure. The debut of the new system took place at the recent Heart Failure Society of America ("HFSA") conference in Philadelphia, PA. ReDSTM PRO is optimized for the point-of-care market, designed for use in hospitals and sub-acute facilities. ReDSTM PRO utilizes non-invasive low energy radio frequency tec
Aug 21, 2019 05:00 pm ET
Medicure Announces Settlement of Patent Infringement Action
WINNIPEG, Aug. 21, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Gland Pharma Ltd. ("Gland") in the U.S. District Court for the District of New Jersey, which alleged infringement of Medicure's U.S. Patent No. 6,770,660 ("the '660 patent"). As part of the settlement, Gland has acknowledged that the '660 patent is valid, enforceable and infringed. The settlement results in the Company entering int
Aug 21, 2019 05:00 pm ET
Medicure Announces Settlement of Patent Infringement Action
WINNIPEG, Aug. 21, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Gland Pharma Ltd. ("Gland") in the U.S. District Court for the District of New Jersey, which alleged infringement of Medicure's U.S. Patent No. 6,770,660 ("the '660 patent"). As part of the settlement, Gland has acknowledged that the '660 patent is valid, enforceable and infringed. The settlement results in the Company enter
Aug 08, 2019 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended June 30, 2019
WINNIPEG, Aug. 8, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2019.
Aug 08, 2019 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended June 30, 2019
WINNIPEG, Aug. 8, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2019.
Aug 02, 2019 09:57 am ET
Medicure Q2 2019 Results and Conference Call Dates
WINNIPEG, Aug. 2, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, will release financial results for the quarter ended June 30, 2019 on Thursday, August 8, 2019. The second quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Friday, August 9, 2019 at 7:30 AM Central Time (8:30 AM Eastern Time).
Aug 02, 2019 09:57 am ET
Medicure Q2 2019 Results and Conference Call Dates
WINNIPEG, Aug. 2, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, will release financial results for the quarter ended June 30, 2019 on Thursday, August 8, 2019. The second quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Friday, August 9, 2019 at 7:30 AM Central Time (8:30 AM Eastern Time).
Jun 26, 2019 06:00 pm ET
Medicure Announces Results of 2019 Annual Meeting of Shareholders
WINNIPEG, June 26, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJD.PK), a pharmaceutical company, today announced the results of its annual meeting of shareholders which took place on June 26, 2019. All director nominees were re-appointed to the Board of Directors (the "Board") and PricewaterhouseCoopers LLP was appointed as auditors as further described in the Company's management proxy circular, dated May 15, 2019.
Jun 10, 2019 05:30 pm ET
Medicure Announces Appoinment of Dr. Neil Owens as President and Chief Operating Officer
WINNIPEG, June 10, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJD.PK), a pharmaceutical company, today announced that Dr. Neil Owens has been appointed President and Chief Operating Officer of the Company effective July 1, 2019. In this capacity, Dr. Owens will be responsible for implementing the Company's strategic plans, and overseeing day-to-day operations, including the advancement and management of new and existing pharmaceutical products. Dr. Albert Friesen has served as the Company's President since May of 2016 and will continue to serve as Chief Exec
May 30, 2019 09:30 am ET
Medicure Announces Renewal of its Normal Course Issuer Bid
WINNIPEG, May 30, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted the Company's notice of intention to make a normal course issuer bid ("NCIB").
May 27, 2019 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended March 31, 2019
WINNIPEG, May 27, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2019.
May 27, 2019 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended March 31, 2019
WINNIPEG, May 27, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2019.
May 22, 2019 06:00 pm ET
Medicure Q1 2019 Results and Conference Call Dates
WINNIPEG, May 22, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, will release financial results for the quarter ended March 31, 2019 on Monday, May 27, 2019. The first quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Tuesday, May 28, 2019 at 7:30 AM Central Time (8:30 AM Eastern Time).
May 22, 2019 06:00 pm ET
Medicure Q1 2019 Results and Conference Call Dates
WINNIPEG, May 22, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, will release financial results for the quarter ended March 31, 2019 on Monday, May 27, 2019. The first quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Tuesday, May 28, 2019 at 7:30 AM Central Time (8:30 AM Eastern Time).
May 15, 2019 05:30 pm ET
Medicure Appoints Ms. Manon Harvey to its Board of Directors
WINNIPEG, May 15, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJD.PK), a pharmaceutical company, today announced the appointment of Manon Harvey CPA, CA, to the Board of Directors.
May 15, 2019 05:30 pm ET
Medicure Appoints Ms. Manon Harvey to its Board of Directors
WINNIPEG, May 15, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJD.PK), a pharmaceutical company, today announced the appointment of Manon Harvey CPA, CA, to the Board of Directors.
Apr 29, 2019 05:30 pm ET
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2018
WINNIPEG, April 29, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter and year ended December 31, 2018.
Apr 29, 2019 05:30 pm ET
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2018
WINNIPEG, April 29, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter and year ended December 31, 2018.
Apr 24, 2019 06:44 pm ET
Medicure to Announce Fiscal Year End 2018 Financial Results on April 29, 2019
WINNIPEG, April 24, 2019 /CNW/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, will release financial results for the year ended December 31, 2018 after markets close on Monday, April 29, 2019. The financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Tuesday, April 30, 2019 at 7:30 AM Central Time (8:30 AM Eastern Time).
Apr 24, 2019 06:44 pm ET
Medicure to Announce Fiscal Year End 2018 Financial Results on April 29, 2019
WINNIPEG, April 24, 2019 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, will release financial results for the year ended December 31, 2018 after markets close on Monday, April 29, 2019. The financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Tuesday, April 30, 2019 at 7:30 AM Central Time (8:30 AM Eastern Time).
Feb 13, 2019 04:00 pm ET
Medicure Provides Update on Release of Holdback Funds from Apicore Sale
WINNIPEG, Feb. 13, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that it has received notice from the purchaser of Medicure's interests in Apicore of potential claims against funds held back in respect of representations and warranties under the Apicore sale agreement. The notice does not contain sufficiently detailed information to enable Medicure to assess the merits or size of the claims at this stage. Nevertheless, Medicure will proceed diligently to investigate the potential claims and attempt to
Feb 13, 2019 04:00 pm ET
Medicure Provides Update on Release of Holdback Funds from Apicore Sale
WINNIPEG, Feb. 13, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that it has received notice from the purchaser of Medicure's interests in Apicore of potential claims against funds held back in respect of representations and warranties under the Apicore sale agreement. The notice does not contain sufficiently detailed information to enable Medicure to assess the merits or size of the claims at this stage. Nevertheless, Medicure will proceed diligently to investigate the potential claims and atte
Jan 28, 2019 04:00 pm ET
Medicure Announces Agreement to Market ReDS™ Device for Congestive Heart Failure Patients in the United States
INVESTS US$10.0 MILLION IN SENSIBLE MEDICAL
Jan 28, 2019 04:00 pm ET
Medicure Announces Agreement to Market ReDS™ Device for Congestive Heart Failure Patients in the United States
INVESTS US$10.0 MILLION IN SENSIBLE MEDICAL
Nov 20, 2018 04:00 pm ET
Medicure reports financial results for quarter ended September 30, 2018
WINNIPEG, Nov. 20, 2018 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2018.
Nov 20, 2018 04:00 pm ET
Medicure reports financial results for quarter ended September 30, 2018
WINNIPEG, Nov. 20, 2018 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2018.
Nov 16, 2018 04:40 pm ET
Medicure Files Patent Infringement Action
WINNIPEG, Nov. 16, 2018 /CNW/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has filed a patent infringement action against Gland Pharma Ltd. ("Gland") in the U.S. District Court for the District of New Jersey, alleging infringement of U.S. Patent No. 6,770,660 ("the '660 patent").
Nov 16, 2018 04:40 pm ET
Medicure Files Patent Infringement Action
WINNIPEG, Nov. 16, 2018 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has filed a patent infringement action against Gland Pharma Ltd. ("Gland") in the U.S. District Court for the District of New Jersey, alleging infringement of U.S. Patent No. 6,770,660 ("the '660 patent").
Nov 14, 2018 02:50 pm ET
Medicure Q3 2018 Results and Conference Call Dates
WINNIPEG, Nov. 14, 2018 /CNW/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended September 30, 2018 on Tuesday, November 20, 2018. The third quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Wednesday, November 21, 2018 at 7:30 AM Central Time (8:30 AM Eastern Time).
Nov 14, 2018 02:50 pm ET
Medicure Q3 2018 Results and Conference Call Dates
WINNIPEG, Nov. 14, 2018 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended September 30, 2018 on Tuesday, November 20, 2018. The third quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Wednesday, November 21, 2018 at 7:30 AM Central Time (8:30 AM Eastern Time).
Aug 15, 2018 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended June 30, 2018
WINNIPEG, Aug. 15, 2018 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2018.
Aug 15, 2018 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended June 30, 2018
WINNIPEG, Aug. 15, 2018 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2018.
Aug 13, 2018 11:30 am ET
Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection
WINNIPEG, Aug. 13, 2018 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that the United States Food and Drug Administration ("FDA") has approved its Abbreviated New Drug Application ("ANDA") for Sodium Nitroprusside Injection 50 mg/2 mL (25 mg/mL) single dose vial ("SNP"), a generic intravenous cardiovascular drug product. SNP is indicated for the immediate reduction of blood pressure for adult and pediatric patients in hypertensive crisis. The product is also indicated for producing controlled hypot
Aug 13, 2018 11:30 am ET
Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection
WINNIPEG, Aug. 13, 2018 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that the United States Food and Drug Administration ("FDA") has approved its Abbreviated New Drug Application ("ANDA") for Sodium Nitroprusside Injection 50 mg/2 mL (25 mg/mL) single dose vial ("SNP"), a generic intravenous cardiovascular drug product. SNP is indicated for the immediate reduction of blood pressure for adult and pediatric patients in hypertensive crisis. The product is also indicated for producing controlle
Aug 08, 2018 05:00 pm ET
Medicure Q2 2018 Results and Conference Call Dates
WINNIPEG, Aug. 8, 2018 /CNW/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended June 30, 2018 on Wednesday, August 15, 2018. The second quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, August 16, 2018 at 7:30 AM Central Time (8:30 AM Eastern Time).
Aug 08, 2018 05:00 pm ET
Medicure Q2 2018 Results and Conference Call Dates
WINNIPEG, Aug. 8, 2018 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended June 30, 2018 on Wednesday, August 15, 2018. The second quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, August 16, 2018 at 7:30 AM Central Time (8:30 AM Eastern Time).
May 23, 2018 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended March 31, 2018
WINNIPEG, May 23, 2018 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2018.
May 23, 2018 05:30 pm ET
Medicure Reports Financial Results for Quarter Ended March 31, 2018
WINNIPEG, May 23, 2018 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2018.
May 17, 2018 06:00 pm ET
Medicure Q1 2018 Results and Conference Call Dates
WINNIPEG, May 17, 2018 /CNW/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the first quarter ended March 31, 2018 on Wednesday, May 23, 2018. The first quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, May 24, 2018 at 7:30 AM Central Time (8:30 AM Eastern Time).
May 17, 2018 06:00 pm ET
Medicure Q1 2018 Results and Conference Call Dates
WINNIPEG, May 17, 2018 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the first quarter ended March 31, 2018 on Wednesday, May 23, 2018. The first quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Thursday, May 24, 2018 at 7:30 AM Central Time (8:30 AM Eastern Time).
May 17, 2018 05:00 pm ET
Medicure Announces Normal Course Issuer Bid
WINNIPEG, May 17, 2018 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted the Company's notice of intention to make a normal course issuer bid ("NCIB").
May 17, 2018 05:00 pm ET
Medicure Announces Normal Course Issuer Bid
WINNIPEG, May 17, 2018 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted the Company's notice of intention to make a normal course issuer bid ("NCIB").
May 02, 2018 08:25 am ET
IIROC Trading Resumption - MPH
VANCOUVER, May 2, 2018 /CNW/ - Trading resumes in:
May 01, 2018 10:47 pm ET
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2017
WINNIPEG, May 1, 2018 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter and year ended December 31, 2017.
May 01, 2018 10:47 pm ET
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2017
WINNIPEG, May 1, 2018 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter and year ended December 31, 2017.
May 01, 2018 08:22 am ET
IIROC Trading Halt - MPH
VANCOUVER, May 1, 2018 /CNW/ - The following issues have been halted by IIROC:
May 01, 2018 07:00 am ET
Medicure announces availability of ZYPITAMAG™ (pitavastatin) in the U.S.
WINNIPEG, May 1, 2018 /CNW/ - Medicure (TSXV:MPH) today announced that pitavastatin magnesium (ZYPITAMAGTM) tablets are now available in retail pharmacies throughout the United States. ZYPITAMAGTM, a statin (HMG-CoA reductase inhibitor) medication approved by the U.S. Food and Drug Administration (FDA) in July 2017, is available in strengths of 1 mg, 2 mg and 4 mg. ZYPITAMAGTM is indicated for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet, to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apo
May 01, 2018 07:00 am ET
Medicure announces availability of ZYPITAMAG™ (pitavastatin) in the U.S.
WINNIPEG, May 1, 2018 /PRNewswire/ - Medicure (TSXV:MPH) today announced that pitavastatin magnesium (ZYPITAMAGTM) tablets are now available in retail pharmacies throughout the United States. ZYPITAMAGTM, a statin (HMG-CoA reductase inhibitor) medication approved by the U.S. Food and Drug Administration (FDA) in July 2017, is available in strengths of 1 mg, 2 mg and 4 mg. ZYPITAMAGTM is indicated for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet, to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-
Apr 24, 2018 09:39 am ET
Medicure to Announce Fiscal Year End 2017 Financial Results on April 30, 2018
WINNIPEG, April 24, 2018 /CNW/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the year ended December 31, 2017 after market close on Monday, April 30, 2018. Medicure will hold a conference call and webcast regarding the results on Tuesday, May 1, 2018 at 7:30 AM Central Time (8:30 AM Eastern Time).
Apr 24, 2018 09:39 am ET
Medicure to Announce Fiscal Year End 2017 Financial Results on April 30, 2018
WINNIPEG, April 24, 2018 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the year ended December 31, 2017 after market close on Monday, April 30, 2018. Medicure will hold a conference call and webcast regarding the results on Tuesday, May 1, 2018 at 7:30 AM Central Time (8:30 AM Eastern Time).
Mar 28, 2018 06:00 pm ET
Medicure Announces Further Up-Date on PREXXARTAN®
WINNIPEG, March 28, 2018 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that further to its press release of March 19, 2018, Medicure has been named in a civil claim in Florida from the third party manufacturer of PREXXARTAN® (valsartan) oral solution against Carmel Biosciences, Inc. ("Carmel"). The claim disputes the rights granted by Carmel to the Company with respect to PREXXARTAN®. The Company believes the claim against it is without merit and will defend itself against the claim.
Mar 28, 2018 06:00 pm ET
Medicure Announces Further Up-Date on PREXXARTAN®
WINNIPEG, March 28, 2018 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that further to its press release of March 19, 2018, Medicure has been named in a civil claim in Florida from the third party manufacturer of PREXXARTAN® (valsartan) oral solution against Carmel Biosciences, Inc. ("Carmel"). The claim disputes the rights granted by Carmel to the Company with respect to PREXXARTAN®. The Company believes the claim against it is without merit and will defend itself against the claim.
Mar 19, 2018 07:30 am ET
Medicure Announces an Up-Date on PREXXARTAN® Launch
WINNIPEG, March 19, 2018 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that it has placed its PREXXARTAN® (valsartan) oral solution project on hold pending the resolution of a dispute that Medicure has become aware of between the owner of the New Drug Application ("NDA"), Carmel Biosciences, Inc. ("Carmel") and the third party manufacturer of the product.
Mar 19, 2018 07:30 am ET
Medicure Announces an Up-Date on PREXXARTAN® Launch
WINNIPEG, March 19, 2018 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that it has placed its PREXXARTAN® (valsartan) oral solution project on hold pending the resolution of a dispute that Medicure has become aware of between the owner of the New Drug Application ("NDA"), Carmel Biosciences, Inc. ("Carmel") and the third party manufacturer of the product.
Mar 07, 2018 04:30 pm ET
Zydus partners with Medicure to launch its NDA Product, ZYPITAMAG (pitavastatin) in the U.S.
This marks Zydus' first branded product launch in the U.S. and Medicure's second cardiovascular drug on the U.S. market
Mar 07, 2018 04:30 pm ET
Zydus partners with Medicure to launch its NDA Product, ZYPITAMAG (pitavastatin) in the U.S.
This marks Zydus' first branded product launch in the U.S. and Medicure's second cardiovascular drug on the U.S. market
Feb 01, 2018 09:23 am ET
Medicure Announces Receipt of Deferred Proceeds from Apicore Sale
WINNIPEG, Feb. 1, 2018 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that it has received the deferred purchase price proceeds of approximately US$50 million from the sale of its interests in Apicore to an arm's length, pharmaceutical company (the "Buyer"), a transaction that closed and was announced in October 2017.
Feb 01, 2018 09:23 am ET
Medicure Announces Receipt of Deferred Proceeds from Apicore Sale
WINNIPEG, Feb. 1, 2018 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that it has received the deferred purchase price proceeds of approximately US$50 million from the sale of its interests in Apicore to an arm's length, pharmaceutical company (the "Buyer"), a transaction that closed and was announced in October 2017.
Dec 19, 2017 04:30 pm ET
Medicure Announces FDA Approval Received for Prexxartan®
WINNIPEG, Dec. 19, 2017 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that Carmel Biosciences, Inc. ("Carmel") has received final approval of its New Drug Application from the US Food and Drug Administration ("FDA") for Prexxartan® (valsartan) oral solution. The FDA approval of Prexxartan® makes it the first and only approved oral liquid dosage form of the angiotensin II receptor blocker ("ARB") valsartan in the United States.
Dec 19, 2017 04:30 pm ET
Medicure Announces FDA Approval Received for Prexxartan®
WINNIPEG, Dec. 19, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that Carmel Biosciences, Inc. ("Carmel") has received final approval of its New Drug Application from the US Food and Drug Administration ("FDA") for Prexxartan® (valsartan) oral solution. The FDA approval of Prexxartan® makes it the first and only approved oral liquid dosage form of the angiotensin II receptor blocker ("ARB") valsartan in the United States.
Dec 14, 2017 09:17 am ET
Medicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the U.S.
WINNIPEG, Dec. 14, 2017 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that, through its subsidiary, Medicure International Inc., it has acquired, from a large multinational pharmaceutical company, an exclusive license to sell and market a branded cardiovascular drug, for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia, in the United States and its territories. The licensing agreement is for a term of seven years with extensions to the term available.
Dec 14, 2017 09:17 am ET
Medicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the U.S.
WINNIPEG, Dec. 14, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that, through its subsidiary, Medicure International Inc., it has acquired, from a large multinational pharmaceutical company, an exclusive license to sell and market a branded cardiovascular drug, for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia, in the United States and its territories. The licensing agreement is for a term of seven years with extensions to the term available.
Nov 21, 2017 04:00 pm ET
Medicure Reports Financial Results for Quarter Ended September 30, 2017
WINNIPEG, Nov. 21, 2017 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2017.
Nov 21, 2017 04:00 pm ET
Medicure Reports Financial Results for Quarter Ended September 30, 2017
WINNIPEG, Nov. 21, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2017.
Nov 17, 2017 04:00 pm ET
Medicure Announces Repayment of Outstanding Debt
WINNIPEG, Nov. 17, 2017 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that it has repaid in full its loans with the Manitoba Development Corporation ("MDC") and Crown Capital Fund IV, LP, an investment fund managed by Crown Capital Partners Inc. ("Crown").
Nov 17, 2017 04:00 pm ET
Medicure Announces Repayment of Outstanding Debt
WINNIPEG, Nov. 17, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that it has repaid in full its loans with the Manitoba Development Corporation ("MDC") and Crown Capital Fund IV, LP, an investment fund managed by Crown Capital Partners Inc. ("Crown").
Nov 15, 2017 06:00 pm ET
Medicure Q3 Results and Conference Call Dates
WINNIPEG, Nov. 15, 2017 /CNW/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, will release financial results for the third quarter on Tuesday, November 21, 2017. The third quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Wednesday, November 22, 2017 at 7:30 AM Central Time (8:30 AM Eastern Time).
Nov 15, 2017 06:00 pm ET
Medicure Q3 Results and Conference Call Dates
WINNIPEG, Nov. 15, 2017 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, will release financial results for the third quarter on Tuesday, November 21, 2017. The third quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Wednesday, November 22, 2017 at 7:30 AM Central Time (8:30 AM Eastern Time).
Oct 31, 2017 07:00 pm ET
Medicure Acquires Exclusive License to Sell and Market PREXXARTAN® in the U.S. from Carmel Biosciences
WINNIPEG, Oct. 31, 2017 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that, through its subsidiary, Medicure International Inc., it has acquired an exclusive license to sell and market PREXXARTAN® (valsartan) oral solution in the United States and its territories from Carmel Biosciences, Inc. ("Carmel") for a seven year term with extensions to the term available.
Oct 31, 2017 07:00 pm ET
Medicure Acquires Exclusive License to Sell and Market PREXXARTAN® in the U.S. from Carmel Biosciences
WINNIPEG, Oct. 31, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that, through its subsidiary, Medicure International Inc., it has acquired an exclusive license to sell and market PREXXARTAN® (valsartan) oral solution in the United States and its territories from Carmel Biosciences, Inc. ("Carmel") for a seven year term with extensions to the term available.
Oct 03, 2017 10:24 am ET
IIROC Trading Resumption - MPH
VANCOUVER, Oct. 3, 2017 /CNW/ - Trading resumes in:
Oct 03, 2017 09:58 am ET
Medicure Announces Sale of Apicore Business
WINNIPEG, Oct. 3, 2017 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that it has sold its interests in Apicore to an arm's length, pharmaceutical company (the "Buyer").
Oct 03, 2017 09:58 am ET
Medicure Announces Sale of Apicore Business
WINNIPEG, Oct. 3, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that it has sold its interests in Apicore to an arm's length, pharmaceutical company (the "Buyer").
Oct 03, 2017 09:10 am ET
IIROC Trade Resumption - Medicure Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 3, 2017) - Trading resumes in:
Oct 02, 2017 11:42 am ET
IIROC Trading Halt - MPH
VANCOUVER, Oct. 2, 2017 /CNW/ - The following issues have been halted by IIROC:
Oct 02, 2017 10:28 am ET
IIROC Trade Halt - Medicure Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2017) - The following issues have been halted by IIROC:
Aug 07, 2017 06:00 pm ET
Medicure Reports Financial Results for Quarter Ended June 30, 2017
WINNIPEG, Aug. 7, 2017 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2017.
Aug 07, 2017 06:00 pm ET
Medicure Reports Financial Results for Quarter Ended June 30, 2017
WINNIPEG, Aug. 7, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2017.
Aug 02, 2017 06:00 pm ET
Medicure Q2 Results and Conference Call Dates
WINNIPEG, Aug. 2, 2017 /CNW/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the second quarter on Monday, August 7, 2017. The second quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Tuesday, August 8, 2017 at 7:30 AM Central Time (8:30 AM Eastern Time).
Aug 02, 2017 06:00 pm ET
Medicure Q2 Results and Conference Call Dates
WINNIPEG, Aug. 2, 2017 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the second quarter on Monday, August 7, 2017. The second quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Tuesday, August 8, 2017 at 7:30 AM Central Time (8:30 AM Eastern Time).
Jul 12, 2017 07:00 pm ET
Medicure Closes Acquisition of Additional Interests in Apicore
WINNIPEG, July 12, 2017 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a leading Canadian specialty pharmaceutical company, is pleased to announce that it has closed the acquisition of additional interests in Apicore Inc. and Apicore LLC (together "Apicore") from Apicore's founding shareholders as previously announced on July 10, 2017. The acquisition, for US$24.5 million, represents approximately 32% of the fully diluted ownership of Apicore and brings Medicure's ownership in Apicore Inc. to approximately 98% (94% on a fully diluted basis).
Jul 12, 2017 07:00 pm ET
Medicure Closes Acquisition of Additional Interests in Apicore
WINNIPEG, July 12, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a leading Canadian specialty pharmaceutical company, is pleased to announce that it has closed the acquisition of additional interests in Apicore Inc. and Apicore LLC (together "Apicore") from Apicore's founding shareholders as previously announced on July 10, 2017. The acquisition, for US$24.5 million, represents approximately 32% of the fully diluted ownership of Apicore and brings Medicure's ownership in Apicore Inc. to approximately 98% (94% on a fully diluted basis).
Jul 10, 2017 07:34 pm ET
Medicure Exercises Option to Acquire Additional Interests in Apicore
WINNIPEG, July 10, 2017 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a leading Canadian specialty pharmaceutical company, is pleased to announce that it and its wholly owned Mauritius subsidiary have exercised their option (the "Option") to acquire additional interests in Apicore Inc. and Apicore LLC (together "Apicore") from Apicore's founding shareholders. The Option exercise allows for the acquisition of all of the shares of Apicore Inc. and Apicore LLC held by the founding shareholders (representing approximately 32% of the fully diluted ownership of Apicor
Jul 10, 2017 07:34 pm ET
Medicure Exercises Option to Acquire Additional Interests in Apicore
WINNIPEG, July 10, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a leading Canadian specialty pharmaceutical company, is pleased to announce that it and its wholly owned Mauritius subsidiary have exercised their option (the "Option") to acquire additional interests in Apicore Inc. and Apicore LLC (together "Apicore") from Apicore's founding shareholders. The Option exercise allows for the acquisition of all of the shares of Apicore Inc. and Apicore LLC held by the founding shareholders (representing approximately 32% of the fully diluted ownership of
Jul 03, 2017 09:00 am ET
Medicure Provides Update on Apicore Purchase Option
WINNIPEG, July 3, 2017 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a leading Canadian specialty pharmaceutical company, announced today that the Company's option (the "Option") to acquire additional shares in Apicore, which otherwise would have expired today, has been extended. The Option covers an additional minority interest in Apicore (the "Minority Interest") currently representing approximately 32% of the fully diluted shares of Apicore. The Minority Interest is held by Apicore's founding shareholders. Medicure currently owns approximately 62% of the fu
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
